These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 9883011)

  • 21. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
    Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
    Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New mediators of immunity and inflammation in inflammatory bowel disease.
    Monteleone G; Fina D; Caruso R; Pallone F
    Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in biological therapy for inflammatory bowel disease.
    Kurtovic J; Segal I
    Trop Gastroenterol; 2004; 25(1):9-14. PubMed ID: 15303463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immune response in inflammatory bowel disease.
    Brown SJ; Mayer L
    Am J Gastroenterol; 2007 Sep; 102(9):2058-69. PubMed ID: 17561966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease.
    Vossenkämper A; Hundsrucker C; Page K; van Maurik A; Sanders TJ; Stagg AJ; Das L; MacDonald TT
    Gastroenterology; 2014 Jul; 147(1):172-83. PubMed ID: 24704524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
    Catalan-Serra I; Brenna Ø
    Hum Vaccin Immunother; 2018; 14(11):2597-2611. PubMed ID: 29624476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome.
    Raddatz D; Bockemühl M; Ramadori G
    Eur J Gastroenterol Hepatol; 2005 May; 17(5):547-57. PubMed ID: 15827446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
    Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
    Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune system alterations in patients with inflammatory bowel disease during remission.
    Sventoraityte J; Zvirbliene A; Kiudelis G; Zalinkevicius R; Zvirbliene A; Praskevicius A; Kupcinskas L; Tamosiūnas V
    Medicina (Kaunas); 2008; 44(1):27-33. PubMed ID: 18277086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytokine blockade in inflammatory bowel diseases.
    Perrier C; Rutgeerts P
    Immunotherapy; 2011 Nov; 3(11):1341-52. PubMed ID: 22053885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Changing paradigm in the management of inflammatory bowel disease].
    Jang BI
    Korean J Gastroenterol; 2015 May; 65(5):268-72. PubMed ID: 25998972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted therapies in inflammatory bowel disease.
    Siegmund B
    Dig Dis; 2009; 27(4):465-9. PubMed ID: 19897961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological disorders in inflammatory bowel disease and immunotherapeutic implications.
    Amati L; Caradonna L; Jirillo E; Caccavo D
    Ital J Gastroenterol Hepatol; 1999 May; 31(4):313-25. PubMed ID: 10425578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy].
    Ochsenkühn T; Sackmann M; Göke B
    Radiologe; 2003 Jan; 43(1):1-8. PubMed ID: 12552369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current, experimental, and future treatments in inflammatory bowel disease: a clinical review.
    Hvas CL; Bendix M; Dige A; Dahlerup JF; Agnholt J
    Immunopharmacol Immunotoxicol; 2018 Dec; 40(6):446-460. PubMed ID: 29745777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease.
    Kugathasan S; Saubermann LJ; Smith L; Kou D; Itoh J; Binion DG; Levine AD; Blumberg RS; Fiocchi C
    Gut; 2007 Dec; 56(12):1696-705. PubMed ID: 17682002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
    Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.
    Bouguen G; Chevaux JB; Peyrin-Biroulet L
    World J Gastroenterol; 2011 Feb; 17(5):547-56. PubMed ID: 21350703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.